BGNE Stock Overview
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$194.47|
|52 Week High||US$426.56|
|52 Week Low||US$118.18|
|1 Month Change||3.04%|
|3 Month Change||44.89%|
|1 Year Change||-39.50%|
|3 Year Change||46.24%|
|5 Year Change||173.82%|
|Change since IPO||586.69%|
Recent News & Updates
FDA defers action on Novartis/BeiGene's tislelizumab for esophagus cancer citing inspection woes
The U.S. Food and Drug Administration (FDA) deferred action on approving BeiGene (NASDAQ:BGNE) and Novartis' (NYSE:NVS) tislelizumab for esophageal cancer as the agency was unable to carry out required inspections in China due to COVID-19 related travel restrictions. BeiGene's biologics license application (BLA) was seeking approval of tislelizumab as a second-line (2L) therapy for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC). The FDA was expected to take a decision by July 12, after accepting the BLA in September 2021. BeiGene (BGNE) said the FDA was deferring action on the application until the inspections are complete and did not not provide a new expected action date. The BLA remains under review. "We are working with our partner, Novartis, to facilitate the required inspections and bring tislelizumab to patients with second-line esophageal cancer in the U.S. following regulatory approval," said BeiGene's Co-Founder, Chairman and CEO John Oyler. The BLA was backed by data from a phase 3 trial called RATIONALE 302.
BeiGene in pact with InnoRNA to develop messenger RNA-based therapies
Chinese biotechnology company, BeiGene (NASDAQ:BGNE) announced Wednesday an agreement to develop messenger RNA-based therapies in partnership with InnoRNA, a biotech with expertise in LNP-based delivery technology and mRNA drug discovery. Per the terms of the collaboration, the two companies will jointly develop multiple mRNA-LNP programs. BeiGene (BGNE) will have the exclusive global rights for the development and commercialization of the product candidates jointly discovered by the two companies. In return, InnoRNA will receive an upfront cash payment in addition to tiered royalties and milestone payments based on certain development, regulatory, and commercial events. The company will also receive a non-exclusive license to InnoRNA’s proprietary LNP Technology in exchange for an additional upfront cash payment and milestone payments to InnoRNA. Read: In June, Citi argued BeiGene (BGNE) could benefit as China eases COVID-driven travel restrictions.
|BGNE||US Biotechs||US Market|
Return vs Industry: BGNE underperformed the US Biotechs industry which returned -24.5% over the past year.
Return vs Market: BGNE underperformed the US Market which returned -12.9% over the past year.
|BGNE Average Weekly Movement||13.3%|
|Biotechs Industry Average Movement||12.9%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.1%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: BGNE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: BGNE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors.
BeiGene Fundamentals Summary
|BGNE fundamental statistics|
Is BGNE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BGNE income statement (TTM)|
|Cost of Revenue||US$1.78b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-19.38|
|Net Profit Margin||-187.65%|
How did BGNE perform over the long term?See historical performance and comparison
Is BGNE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BGNE?
Other financial metrics that can be useful for relative valuation.
|What is BGNE's n/a Ratio?|
Price to Sales Ratio vs Peers
How does BGNE's PS Ratio compare to its peers?
|BGNE PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
HZNP Horizon Therapeutics
ALNY Alnylam Pharmaceuticals
Price-To-Sales vs Peers: BGNE is expensive based on its Price-To-Sales Ratio (18.8x) compared to the peer average (14.2x).
Price to Earnings Ratio vs Industry
How does BGNE's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: BGNE is expensive based on its Price-To-Sales Ratio (18.8x) compared to the US Biotechs industry average (16.6x)
Price to Sales Ratio vs Fair Ratio
What is BGNE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||18.8x|
|Fair PS Ratio||5.4x|
Price-To-Sales vs Fair Ratio: BGNE is expensive based on its Price-To-Sales Ratio (18.8x) compared to the estimated Fair Price-To-Sales Ratio (5.4x).
Share Price vs Fair Value
What is the Fair Price of BGNE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BGNE ($194.47) is trading below our estimate of fair value ($1407.42)
Significantly Below Fair Value: BGNE is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is BeiGene forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BGNE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BGNE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BGNE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BGNE's revenue (30.7% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: BGNE's revenue (30.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BGNE is forecast to be unprofitable in 3 years.
Discover growth companies
How has BeiGene performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BGNE is currently unprofitable.
Growing Profit Margin: BGNE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BGNE is unprofitable, and losses have increased over the past 5 years at a rate of 39.2% per year.
Accelerating Growth: Unable to compare BGNE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BGNE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.8%).
Return on Equity
High ROE: BGNE has a negative Return on Equity (-37.82%), as it is currently unprofitable.
Discover strong past performing companies
How is BeiGene's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BGNE's short term assets ($5.9B) exceed its short term liabilities ($1.0B).
Long Term Liabilities: BGNE's short term assets ($5.9B) exceed its long term liabilities ($1.0B).
Debt to Equity History and Analysis
Debt Level: BGNE has more cash than its total debt.
Reducing Debt: BGNE's debt to equity ratio has reduced from 55.4% to 10.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BGNE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BGNE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is BeiGene current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BGNE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BGNE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BGNE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BGNE's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BGNE has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Oyler (54 yo)
Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD16.75M) is about average for companies of similar size in the US market ($USD12.96M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Experienced Management: BGNE's management team is considered experienced (4.7 years average tenure).
Experienced Board: BGNE's board of directors are considered experienced (6.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BGNE insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.6%.
BeiGene, Ltd.'s employee growth, exchange listings and data sources
- Name: BeiGene, Ltd.
- Ticker: BGNE
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$20.122b
- Shares outstanding: 103.47m
- Website: https://www.beigene.com
Number of Employees
- BeiGene, Ltd.
- 55 Cambridge Parkway
- Suite 700W
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/07 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.